Upadacitinib N1-Methyl Ester Impurity
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Upadacitinib N1-Methyl Ester Impurity

● In Stock

Catalogue No.:VE0027856
CAS No.:N/A
Mol. Formula:C16H19N5O2
Mol. Weight:313.35 g/mol

Additional information on

Parent drug

Upadacitinib

IUPAC Name

(3S,4R)-methyl 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e] pyrazin-8-yl)pyrrolidine-1- carboxylate

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

O=C(N1C[C@@H](CC)[C@@H](C2=CN=C3C=NC(NC=C4)=C4N32)C1)OC

InChI

InChI=1S/C16H19N5O2/c1-3-10-8-20(16(22)23-2)9-11(10)13-6-18-14-7-19-15-12(21(13)14)4-5-17-15/h4-7,10-11,17H,3,8-9H2,1-2H3/t10-,11+/m1/s1

Description

Upadacitinib N1-Methyl Ester Impurity is a process-related degradation product encountered during the synthesis and purification of upadacitinib, requiring targeted analytical control to ensure drug substance quality. This impurity is typically monitored at trace levels using orthogonal techniques such as HPLC with UV detection, LC-MS for mass confirmation, and NMR for structural elucidation, enabling reliable identification and quantification. Risk-based mitigation includes optimization of methylation and esterification steps, selective chromatographic purification, and established acceptance criteria consistent with regulatory guidance for impurity qualification. Comprehensive documentation of occurrence, analytical methods, and control strategies supports robust quality assurance and regulatory submissions.

Request a Quote

« * » indique les champs nécessaires

Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.
Products quotation
Name
Url